| Income Statement | 2025-09-30 | 2025-06-30 | 2024-09-30 | |
|---|---|---|---|---|
| Total non-operating income, net | 10,063 | 16,927 | 19,424 | |
| Loss before income taxes | -305,206 | -247,787 | -156,288 | |
| Net loss | -305,206 | -247,787 | -156,288 | |
| Unrealized gain on investments, net | 1,814 | - | 5,675 | |
| Comprehensive loss | -303,392 | - | -150,613 | |
| Net loss per share attributable to common stockholders, basic | -1.61 | -1.31 | -0.94 | |
| Net loss per share attributable to common stockholders, diluted | -1.61 | -1.31 | -0.94 | |
| Weighted average number of shares outstanding, diluted | 189,231,562 | 188,583,288 | 166,843,984 | |
| Weighted-average shares used to compute net loss per share attributable to common stockholders-basic | 189,231,562 | 188,583,288 | 166,843,984 | |
Revolution Medicines, Inc. (RVMD)
Revolution Medicines, Inc. (RVMD)